GoodRx Holdings, Inc. (NASDAQ:GDRX) Receives Average Recommendation of “Moderate Buy” from Analysts

Shares of GoodRx Holdings, Inc. (NASDAQ:GDRX) have received a consensus recommendation of “Moderate Buy” from the twenty brokerages that are covering the stock, Marketbeat reports. One research analyst has rated the stock with a sell recommendation, seven have issued a hold recommendation and twelve have given a buy recommendation to the company. The average 12 month price target among analysts that have covered the stock in the last year is $9.32.

Several equities research analysts recently issued reports on the stock. KeyCorp upgraded shares of GoodRx from a “sector weight” rating to an “overweight” rating and set a $9.00 price objective for the company in a research report on Wednesday, April 10th. TD Cowen boosted their price target on shares of GoodRx from $14.00 to $16.00 and gave the company a “buy” rating in a research note on Thursday, May 16th. Wells Fargo & Company raised shares of GoodRx from an “equal weight” rating to an “overweight” rating and boosted their price target for the company from $7.50 to $10.00 in a research note on Monday, March 25th. Raymond James raised shares of GoodRx from a “market perform” rating to an “outperform” rating and set a $10.00 price target on the stock in a research note on Thursday, May 16th. Finally, Barclays boosted their price target on shares of GoodRx from $9.00 to $10.00 and gave the company an “overweight” rating in a research note on Monday, May 20th.

Institutional Investors Weigh In On GoodRx

Large investors have recently modified their holdings of the company. Beacon Capital Management LLC purchased a new stake in shares of GoodRx in the 1st quarter valued at approximately $28,000. Citigroup Inc. increased its position in shares of GoodRx by 301.7% in the 3rd quarter. Citigroup Inc. now owns 7,997 shares of the company’s stock valued at $45,000 after purchasing an additional 6,006 shares during the last quarter. Gerber LLC purchased a new stake in shares of GoodRx in the 4th quarter valued at approximately $75,000. Innealta Capital LLC purchased a new stake in shares of GoodRx in the 4th quarter valued at approximately $91,000. Finally, Schnieders Capital Management LLC purchased a new stake in shares of GoodRx in the 1st quarter valued at approximately $93,000. 63.77% of the stock is owned by hedge funds and other institutional investors.

GoodRx Price Performance

GoodRx stock opened at $7.81 on Friday. GoodRx has a 12-month low of $4.14 and a 12-month high of $9.37. The stock has a market cap of $2.93 billion, a P/E ratio of -780.22, a PEG ratio of 3.65 and a beta of 1.39. The company has a 50-day moving average price of $7.68 and a 200 day moving average price of $7.00. The company has a current ratio of 6.29, a quick ratio of 6.29 and a debt-to-equity ratio of 1.02.

GoodRx (NASDAQ:GDRX) last released its quarterly earnings data on Thursday, May 9th. The company reported $0.03 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.04 by ($0.01). GoodRx had a positive return on equity of 3.45% and a negative net margin of 0.86%. The firm had revenue of $197.88 million for the quarter, compared to analyst estimates of $196.20 million. Sell-side analysts anticipate that GoodRx will post 0.17 earnings per share for the current year.

About GoodRx

GoodRx Holdings, Inc, together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices.